Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Alphcolin; Audes; CDP choline; CerAxon; Cytidil diphosphocholine; Hipercol; IP 302; Metanervon; Neurex; Neurox; Nicholin; Somazina; Startonyl; Trausan

Latest Information Update: 31 Jul 2013

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer Ferrer; Takeda
  • Class Neuroprotectants; Nootropics; Pyrimidine nucleotides; Small molecules; Trimethyl ammonium compounds
  • Mechanism of Action Hydroxy radical formation inhibitors; Phosphatidylcholine stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Brain injuries; Parkinson's disease; Stroke

Most Recent Events

  • 27 Jan 2006 IVAX Corporation has been acquired by Teva Pharmaceutical Industries
  • 27 Oct 2004 Citicoline has been licensed to IVAX Corporation in USA
  • 04 Jul 2002 Indevus has signed a non-binding memorandum of agreement with a privately held biotechnology company for further development of citicoline in the US and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top